Report on Extraordinary General Meeting held in NeuroSearch A/S

Pursuant to announcement, the Extraordinary General Meeting of NeuroSearch A/S
was held today Wednesday, 20 May 2009. 

The suggested amendments to the Articles of Association were adopted by the
General Meeting: Article 5 following which the Board of Directors is authorised
to increase the company's share capital in one or more issues of up to a total
nominal value of DKK 60,000,000 (3.000.000 shares of DKK 20 each) until 1 April
2014, article 5a following which the Board of Directors is authorised to issue
warrants by one or more issues for up to a total nominal value of DKK
10,000,000 (5,000,000 shares of DKK 20 each) to some or all of the company's or
the company's subsidiaries' employees, Board members and Executive Management
on terms laid down by the Board of Directors for the period ending on 31
December 2010 and article 5k following which the Board of Directors is
authorised to raise loan against issue of convertible bonds in one or more
issues until 31.12.2010 by up to DKK 162,000,000. Furthermore, it was decided
to amend article 8 of the Articles of Association to state I-NVESTOR DANMARK
A/S, Kongevejen 418, DK-2840 Holte as the company's registrar of shareholders. 


Flemming Pedersen 
CEO


Contact persons:
Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103 



NeuroSearch  -  Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq
OMX Copenhagen. The company's core business covers the development of novel
drugs, based on a broad and well-established drug discovery platform focusing
on ion channels and central nervous system (CNS) disorders. A substantial share
of the activities is partner financed through strategic alliances with Eli
Lilly and Company and GlaxoSmithKline (GSK) and a license collaboration with
Abbott. The drug pipeline comprises seven clinical (Phase I-III) development
programmes: ACR16 for Huntington's disease (Phase III), tesofensine for obesity
(Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott,
ACR325 to treat dyskinesias in Parkinson's disease (Phase II ready), ACR343 for
schizophrenia (Phase I), ABT-560 for the treatment of various CNS disorders
(Phase I) in collaboration with Abbott, and NSD-788 for anxiety/depression
(Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug
candidates and holds equity interests in several biotech companies.